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DJ.SULEr A~m IXSULil'I ASSAYS 
Insulin Production 
The beta cells of the islands of Lancerhans of the pancreas 
are the site of insulin synthesis. Jslet cells lie close together 
with only an occasional space betITeen them. Each cell is apparent-
ly encircled by its own plasma me~brane but at times it is difficult 
to determine the limits of individual membranes especially along 
those portions of a cell Tihich adhere to adjacent cells. 
The typical beta coll is many-sided and irregular in outline. 
It contains a varying nu::.1ber of rather course granuleso Some cells 
in a given islet are l:i.. te.:call;:i filled with granules nhile others 
are almost e~pty. The granules themselves are not evenly distrib-
uted throughout a cell but are often densely packed in a portion 
of the cell which lies along capillaries. These granules, which 
are virtually electron-o?aque, contain insulin and proinsulin that 
has been formed ':Ti thin tbe cell. In man, the granules aay be rec-
tangular in outline and crystalline in appearance. Variation in the 
shape of the granules may reflect a difference in insulin structure 
or in the type of materials wi t!1 which the insulin is associated 
in the granules. Since granules are too large to represent sincle 
molecules of L1suJ..in, it is po::::si"!Jle that the actual amino acid 
sequence in the insulin ~i;ht influ8nce the way in which the mole-
cules can be urranced ~ithin the cranule. Similarly, the struc-
2 
ture of the protein which binds insulin may impart certain char-
acteristics of form to the granule. 
In order to function as a hormone, insulin must first break 
out of its capsule and leave the beta cell. The events which 
bring insulin to its "target tissue" begin with the migration of 
fully formed insulin sacs from their formation sites. The mech-
anism by which insulin granules are released when they reach the 
cell surface is not fully known. However, it is thought that 
the cell's plasma membrane and the capsule membrane fuse upon con-
tact and that these membranes rupture at the point of contact (73). 
As a result, a passageway is thereby provided for the insulin 
granule across two membranes and thus out of the beta cell. Al-
though it is presumed that granules of insulin shod their enve-
loping capsules when they leave the beta. cell, as described, free 
granules have not been observed. It is likely, therefore, that 
each granule undergoes a transformation at the moment of release. 
The insulin that continues on toward the lumen of the nearest 
capillary maybe in a non-sranular form, or it may even be in the 
soluble state, al thou~;:1 perhaps bound to protein. 
Tho Insulin Molecule 
Insulin is a protein consisting of fifty-one amino acids and 
has a minimum molecular weight of 6,000. The molecule is coLlpOsed 
of two polypeptide chains desi2:nated "A" and "B" which are connec-
ted by two interchain disulfide bridges of cysteine (See Figure I). 
r 
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AMINO ACID 
SEQUENCE 
8 ALA 
9 SER 
21 
30 
"A" CHAIN 
NH, 
COOH 
"B" CHAIN 
NH, 
ALA-':--___ _ 
I 
COOH 
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3 
GLU 
LEU 
PRO 
4 
The "A" chain of insulin contains an intrachain disulfide bridge 
within which a species difference in amino acid composition occurs 
primarily at positions 8, 9, and 10. A species difference also 
occurs at the carboxy terminus, position 30, of the "B" chain 
(See Chart I). 
~ulating Insulin 
The insulin secreted by the pancreas has a rapid turnover in 
man, the half-life of labeled insulin being of the order of forty 
minutes. Rapid release from the pancreas along with this rapid 
turnover implies th2t the body is able to call upon a relatively 
large quantity of insulin to satisfy metabolic needs on short no-
tice and is at the same time protected against the dangers of hypo-
glycemia. 
The insulin secreted by the pancreas enters the portal vein 
and passes through the liver before it is delivered to the syste-
mic circulation. A substantial amount of this insulin is trapped 
by the liver. In fact, after portal injection of labeled insulin, 
approxinately fifty percent of the administered dose was found to 
be bound to the liver in a sincle transhcpatic circulation (55). 
Thus the amount of available insulin is determined in larce part 
by the liver, which not only traps insulin but degrades it as well. 
It has also been shown that insulin ~hich is not trapped or degraded 
may be ~odified so that it leaves the liver in a physiologically 
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CHART I 
SOME SPECIES DIFF:'.:::RZi'TCES I~·I -~"rpm ACID SEQUEI;c.s OF MAHMALIA~T INSULINS 
POSITIOl"TS 
"A" CHAIN 11 B11 CHAIN 
t") 0 10 30 () 
./ 
Human Threonine Serino Isoleucine Threonine 
Beef Alanine Serine Valine Alanine 
Pork Threonine Serine Isoleucine Alanine 
OTHEn SPECI~~S 
Rabbit Th1~eonine Serino Isoleucine Serine 
Doc Threonine Serine Isoleucino Alanine 
Sheep Alanine Glycine Valine Alanine 
Horse Threonine Glycine Isoleucine Alanine 
inactive protein-comple~ form (37). The nature of this complexed 
form of insulin has been the center of much controversy in the 
field of diabetes research. A large part of the conflict stems 
from the way in which insulin is assayed. It is, therefore, appro-
priate to consider, briefly, the various procedures which have 
been used for the assay of insulin. 
CHAPTER II 
ASSAYS OF INSULIN 
The most commonly employed procedures for the assay of insu-
lin are: tho rat diaphragm bioassay, the epididymal fat-pad bio-
assay, the radioimmunoassay and :..:: vivo bioassays. The results of 
most assays are reported in terms of units of insulin. One unit 
of insulin is defined as 1/24 mg of insulin (81). 
The first assay to be e:nployed by researchers was the in .YiY.£ 
bioassay. Since the accepted criterion of insulin action is a fall 
in the concentration of blood sugar, the first insulin assays made 
use of this fact. Beigelman, in 1958, measured the change in the 
level of blood sugar in mice (18). The sensitivity of his method 
1vas 1000 uU. This method was modified by Bornstein and Lav:.rence 
(22). He employed hypophysectomized, adrcnalectomized, alloxan 
diabetic rats. With these animals, the range of assayable insulin 
is between fifty and five hundred microunits per milliliter. The 
preparation of test animals for the in yi:.:_52 assays is difficult, 
time consuming and expensive and the mortality rate is very high. 
It is therefore not surprising that these methods were soon aban-
do~ed. Better methods, with improved sensitivity and less inherent 
problems were soon employed. 
Vallence-Owen and Hurlock investigated the addition of insu-
lin to a glucose-containing medium incubated with rat diaphragm 
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muscle (78). The insulin, they found, stimulated glucose uptake 
and glycogen deposition in the muscle. Their assay was sensitive 
to relatively low arnounts of insulin, making it possible to measure 
as little as 25 uU of insulin per ml of test solutions. The assay, 
however, did present some problems. Yalow and Berson shovred that 
in the range up to 100 uU/nl, the insulin concentration must be 
increased by about 225% to produce a 1% change in glucose concen-
tration (84). The best form of the assay is to measure glycogen 
deposition rather than glucose uptake. 1.'li th 14c glycogen incorpor-
ation, the test can be used to measure in the range of 10 to 500 
uU/r:1l of insulin. However, when using even this form of the assay 
another proble;n still persists, namely, the fact that as the serum 
to be assayed is diluted, the activity measured by the assay does 
not fall in pi~oportion with the dilution. A greater amount of 
. 1° . d J... • ' d"l J..• insu in is measure as ac~iva~e~~ upon i u~ion. That is, insulin 
in serum found to contain 74 uU/ml will assay as 200 uU/ml after 
a four fold dilution. This phenomenon has been explained by saying 
that insulin inhi~:Ltors are diluted and thereby more insulin is 
freed to metabolize glucose ( r:.. 7..) v_,; • Evidence for such insulin in-
hibitors in the albumin fraction of serum has been presented by 
Vallence-Owen et.al~ (79). 
An assay ao~ewhat si~ilar to the diaphra;m assay but using 
epididymal fat pads vras developed in 1958 by Hartin and coworkers 
(56). Use is made of the fact that adipose tissue responds to 
insulin vii th an increase in glucose uptake and with a preferential 
9 
oxidation of the sugar via the pentose cycle. In performing this 
assay, the insulin sensitive pararneter which is measured lf.ay be 
glucose uptake, formation of 14 c co2 from l4c-glucose or total 
gas exchange. In its most common form, that of measuring 14co2 
formation, this assay can measure as little as 10 uU/ml of insulin$ 
However, the levels of insulin obtained with this fat pad assay 
are higher than those obtained with the diaphragm assay. For this 
reason the fat pad assay is believed to measure not only insulin 
itself but also insulin-like activity (ILA) which reflects the 
presence of other factors which mimick the effects of insulin in 
the assay procedure. 
The final procedu:'e to be discussed is the radioii:1:-nunoassa;y 
technique. Because of its sensitivity and specificity, this assay, 
which was developed by Yalo~ and Berson, has been heralded as the 
most satisfactor,J• of the in vitro assavs(85). 
- ... 
The radioi~nunoassay is based on the competition of insulin, 
in the sample to be assa::ed, and of radioactive insulin, for reac-
tion v:i th an antiboc.y which is .specific to insulin. The amount of 
radioactive i11sulin bound to antibody, therefore, varies inversely 
with the concentratj.0:1 of insulin j_n tho assay sample (See Figure 
II). 
Several procedures baced on this principle have been worked 
out; they diffor in ~inor details and in the Dethod used for se-
parating insulin bound to antibody fro~ insulin remaining free. 
However, the uost co~nonly used uothod is t~ut of Hales and Randle 
O+TI 
Insulin 
(free)· 
Antibody to insulin 
(guinea pig) 
• '7 ll 
• • ., __. 
• 
• 
Control 
Only radioactive Insulin is used. 
Out of 5 molecules, 4 are bound to 
the antibody and 1 is free. 
R . f bound insulin 4 4 at10 o =-= free insulin 1 
(803 of the radioactive Insulin 
is antibody-bound) 
() c 
Complex of antibody 
+ insulin (bound) 
Measurement 
Nonradioactive Insulin is added 
to the same quantity of radioactive 
Insulin. Out of 5 radioactive molecules, 
2 are now bound and 3 are free. 
R . f bound insulin 2 0 66 atw o . . =-= . free msulm 3 
(403 of the radioactive Insulin 
is antibody-bound) 
ILLUSTPATIOX or TH~ r~ff20?Y OF TH"S RADIOIJ.-E!U:TOAS3AY 
l"igure II 
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(43). This method is also known as the Double A!ltibody Method. 
In this version of the assay procedure, the complex of insulin 
and anti-insulin serum is rendered insoluble by a second antibody. 
This insoluble complex precipitates and is separated from free in-
sulin by filtration. The radioactivity of the precipitate is 
measured and the concentration of insulin in a given sample is 
found by referring to a calibration curve prepared from measure-
ments on pure insulin. The radioimmunoassay can measure insulin 
levels as low as 1 uU/ml of insulin, thus this is the most se~1Si­
tive of the assay procedures described. 
A comparison of value obtained using the different assay 
procedures is shown in Chart II, while the sensitivity of each is 
shovm in Chart III. It is ir.1porta~1t to rej~1ember that all t:1e 
a.ssay procedures, except the radioimmunoassay, measure biologically 
active insulin-like activity (ILA), while the radioimmunoassay 
measures immunologically active free insulin. One cannot make the 
assumption, therefore, that material assayed by the immunoassay, 
which shows little or no insulj_n, co;nplexed to a protein, will not 
be detected by radioiu~unoassay but will be shown to be biologi-
cally active in the fat pad assay. This importo..nt fact is one 
which has led to ~uch controversy in that one investigator ~nay have 
tried to ropoat studies which wore performed by another invostiga-
tor who employed a different assay procedure, thereby obtaining 
conflicting results. 
CHART II 
INSULIIT ASSAY VALU:SS CO>IPA..RED 
Estimated Mean (and Range) of Human 
Plasma Insulin Concentrations 
(Microuni ts/ ml ) 
Method of Assay 
Rat Diaphragr:1 Bi oassay 
(Serum or plasma) 
Rat Epididymal Fat Pad Bioassay 
(Serum or plasna) 
Radioi:~:.:-i1unoassay 
(co~n. 0 t1"ti~~ i·~h1"b1·~·ion Of J.d._:_,~... -- '\...:; _,_..... - l..:.J... -·~ 
b ·- r1 "-. f)' of' 1°' "'] d "1 c-1 1 lin) lll~.l-10 _._ u.Dv .e l .. 1..__; ~-- -"· 
.,., .!.. • 
l' as "ing 
611- (40-80) 
250 (31-900) 
21 ( 0-6r2) 
1? 
After Glucose 
or Feeding 
( 130-800) 
Three to six-
fold increase 
1 l+O (30-300) 
CHART III 
sg1JSITIVITY OF INSULIN ASSAYS 
Radioimmunoassay 1 uU to 1000 uU 
Fat Pad 10 uU to 10 U 
Diaphragm 10 uU to 10 U 
Mouse Hypoclycemia uU to >: 100 U 
Rabbit Hypoglyce~ia > 100 uU to > 100 U 
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CHAPrER III 
-----
INSULI?:'-LIK:S ACTIVITY 
Moloney and Coval in 1955 were able to isolate a specific 
anti-insulin antibody serum which negated the physiological effect 
of crystalline insulin when assayed using adipose tissue or muscle 
(61). However, when the antibody was added to human serum, only 
part of the insulin-like activity in the fat pad assay vras sup--
pressed. In 1961, Slater and coworkers confirmed these findings 
_and used the terr.'.ls "typical" and "atypical" insulin to describe 
the materials assayed (72). HT;ypical" insulin is described as 
that form of L1sulj_n •;.:hi ch ic j_m:Ju:ciologically reactive and 11 atyrii-
cal" insulin that fori:l which is not. 
By using ultracentrifugation techniques, other investigators 
were able to separate these forms of insulin-like activity (67). 
'l'hey reported that the "atypical" forn had a molecular weight in 
excess of 30,000. They also found prolonged acid-ethanol extraction 
of the "atypical" form could convert more than 2/3 of it to typical 
insulin. Analysis of the relative amounts of these two for~s 
sl10wed that typical insulin, measured in the pancreatic venous 
blood, accounted for 90 to 95% of the total ILA, ~hile that in 
hepatic venous blood, accounted for only 50% of the ILA. From 
these studies it was concluded that insulin produced in the beta 
cells rras beinc altered in sor.1e v:ay, in tho liver, ro-::idering it 
15 
immunologically unreactive. 
In 1963, .Froesch and coworkers used gel chromatography, frac-
tional precipitation and electrophoresis to isolate and partially 
purify "atypical" insulin (35). The r.10.terial they isolated was 
imnunologically unreacti ve v;hen assayed by either the diaphragm 
or adipose tissue assay. It showed an activity of 2 uU/ns compared 
to about 25 uU/nc for pure crystalline insulin. Its properties, 
however, were very sinilar to crystalline insulin. It stimulated 
glucose uptake, and carbon dioxide fornation from glucose. It 
induced hypoglyce~ia when injected into nor~al animals and it also 
inhibited lipolysis in the absence of glucose. When passed through 
"P.pl1.,o'e·~ ri 7~ 1 ·n 1~ •• ~ _ ~ c .. t - --:~ i..-~... .,.,,. ·~ .l 5 molar acetic acid, mater:L<::l.l was found \7i th a 
molecular weight of approximately 6,000, thus resembling insulin 
under the same conditions. However, when this atypical insulin was 
oxidized rri th per formic acid, no iirnulin "A" chain was found, using 
electrophoretic ~obility as the idontification nethode Froesch 
postulated fro11 this that so~ne chance in the "A" chain occurred 
in the li vor '.'thich al tors its physical I>roi)ert:Les so th::tt large 
acsregatos of individual nolecules are forned. Under the proper 
conditions these aggregates ~ay disassociate into units of the 
same molecular ueicht and biological activity as native insulin. 
Koen isolated a fraction of serum protein composed larcely 
of albvrnin rrhich had man:l insulin-like properties (51). It in-
creased glucose uptake and glycogen de~osition as measured by the 
diaphragu assay. ~hen incubated with the fat pad, the extract 
16 
accelerated glucose uptake and incorporation of labeled glucose 
into lipid. Hovrever a large portion of the activity was not sup-
pressible by insulin antibodies. 
Antoniades and covrorkers found that serum, when passed through 
a cationic exchange resin, lost almost all of its non-im~mnologic­
ally reactive insulin-like activity (6). The activity could, 
however, be regained from the column by elution with dilute 8.i'1llTIO-
nium hydroxide. The eluted substance had no effect on the diaphragm 
assay but was found to possess considerable insulin-like activity 
when assayed by the fat pad bioassay. This activity could also 
be observed using the diaphraf:-JI assay if the extract was first 
incubated with adipose tissue extract. 
Shaw and Shuey found this regained activity to be inhibited 
by anti-insulin serum indic.:;.ting that there was true insulin in 
the eluate (71). These results, along rri th other experiments from 
his own laboratory, led Antonia.des to postulate that the insulin-
like activity retained by the resin was in the form of a native 
insulin complex with a basic protein (4,7). Ho postulated that the 
binding of the insulin to the resin could only be explained by 
means of the basic protein co~plex, since insulin itself, at phy-
siological pH, is nesatively charGed and migrates electrophoreti-
cally as an anion. The fact that it is bound to a cation exchange 
resin indicated that the insulin in the blood may be transported 
alone with a substn.:'lce having a higher isoelectric point, most like-
ly a protein. Antoniades further postulated that the fat pad ex-
tract ~as able to dissociate the insulin protein complex and re-
17 
store normal activity to the insulin. He renamed these two foros 
of insulin in serur.i as "free" and "bound". He reported that an 
equilibrium existed between the two foros and that the equilibriuo 
was shifted to'ilard the free form upon ingestion of a [;lucose load 
(4). It v1ac further stated that, in some diabetics, their proble;;.1 
micht well be based o.:i o.n inability to convert complexed or "bound" 
insulin into the free fo1~m rapidly enough or to a great enough 
extent to handle the glucose load. Further characterization studies 
were undertaken by Antoniades ( 1 ,1~). Chart IV shows the current 
and available information on the insulin complex. 
Studies on the insulin binding protein were conducted by 
subjecting the resin eluate to centrifugation at pH 9.8.. Collected 
precipitates were pooled, dissolved in acetate buffer and subjected 
to paper electrophoresis (5). Only one substance was evident and 
it appeared to have a substantial positive charge suggesting that 
it was indeed basic in nature. Attempts to form the complex in 
vitro, by incubating serum samples with radioactively tagged insu-
lin, however, failed. This implied that either there is not a 
large amount of free insulin binding protein in the blood or that 
the formation of the complex is more intricate in nature than the 
simple combination of insulin and protein. -Further studies by 
Gershoff, in 1970, however, have shown that perfusion of liver 
with media containins; 74 uU/ml of insulin resulted in a rapid 
loss of im~unoassayable insulin, accompanied by the appearance of 
non-immunoloGically reactive insulin-like activity when using the 
CHART IV 
SOME PROPERTIES OF BOUND, FREE AND CRYSTALLINE INSULIN 
bound insulin free insulin 
Dowex-50x8 (Na+) Cation Anion 
Electrophoretic 'I, ri -globulins 
mobility 
~ 1 -globulins/ albumin 
HoJ.ecular 
weight (pH 8.0) 40,000-60,000 12,000 
Reactivity 
with anti- unreactive reactive 
insulin 
antis era 
Treatment with 
reduced gluta-
thione 
Solubility in 
o.cid-ethanol 
Origin 
inactivation inactivation 
soluble soluble 
Free ir.sulin Pancreas 
(metabolism catalyzed 
in vivo by liver and 
possibly other extra-
pancreatic tissue) 
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crystalline insulin 
Anion 
rx -globul:i.ns/ 1 albumin 
12,000 
reactive 
inactivation 
soluble 
Pancreas 
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rat intraperitoneal assay (37). 
Controversy .9.Y££. Insulin-Like Activity 
Ever since the naming of "free" and "bound" insulin for 
serum insulin-like activity by Antoniades, a controversy has 
continued as to whether there really is such an entity as "bound" 
insulin. Through the years various names have been given to the 
insulin-like activity found by the various investigator·s, such as, 
11 big11 and "little" insulin and "suppressible" and "nonsuppressible" 
insulin-like activity. However no one has proven completely 
whether "bound" or "free" insulin exists or doesn't exist. What 
appears to have boen recognized however is that there is some 
compound that may be retained by a cation exchance resin which 
will elicit effects similar to insulin when assayed by in vitro 
bioassay techniques. The big problem in understanding the issue is 
the fact that most investigators use different assay techniques 
in trying to compare findings. That is, an interchange of the 
radioimmunoassay with the rat diaphragm and rat adipose tissue 
assays is ~adc. As an example of the confusion, in 1968 papers by 
Jakob (49) and one by Roth (64) came out in the affirmative of the 
problem, \'/hile a papor by Meo.de (5 Q) . , . :...> , using m.s ovm isolated 
materials and those eiven to hi~ by Antoniades, came up with 
negative findings, that is to say, he was unable to reproduce 
previous results. 
20 
The problem may be clarified by first realizing that the 
isolation procedure for bound insulin is very difficult, in fact, 
in our own laboratory, because of a change in the resin lot, we 
were unable for a time to isolate the material in a repeatable 
fashion. Also, the problem may be more readily understood if in 
using the terms "bound" and "free" insulin one can assume insulin-
like activity to occur in the bound form without a separation from 
the binding protein. If this idea is accepted, then it can be 
seen how the radioinmunoassay would show no presence of "free" 
insulin while that of an ill vitro bioassay would show physiological 
activity. Thus the key to the problem may indeed be based on the 
afore-mentioned hypothesis. 
It is hoped that the following chapters will help to de~non­
strate this possibility of physiological action without a separa-
tion of the attached insulin from the binding protein. 
CHAPTER IV 
ANTIBODIES AND INSULIN 
Introduction 
-· 
Insulin forms non-covalent bonds when put in contact with 
antibodies to it. This insulin complex has a number of properties 
which are common to it and to insulin complexes which are formed 
i!!, .Y1:.Y.£. It is possible, in fact, that the in .Y1:..Y.£ complex is 
part of an antibody molecule. The reasons for this poGtulation 
are as follows: bound insulin which is formed ~ ~ is known 
to migrate vri th the gamr:ia globulin fraction during serum electro-
phoresis (4). This protein fraction is the one which contains 
the antibodies of the serum. Secondly, in ~ bound insulin is 
immuno·-nonreacti ve and shows no glucose uptake as measured by 
bioassay (4). Thus, if already antibody bound, the insulin could 
not combine further. Thirdly, tolbutamide has been shown to exert 
an effect on both in ~ and in vi.tro complexes as measured by 
the rat diaphragu assay (46). That is to say, both complexes 
regain biological activity when tolbutamide is added to the prep-
aration. Fourthly, the Fab fragment of antibody molecules, that 
is the active antibody site, can be separated from an intact anti-
body molecule by enzymatic digestion. This fragment still retains 
the ability to bind antigen and has a molecular weight of approxi-
mately 50,000. This is approxi~ately the weight attributed to 
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the ill .Y.iY2. protein which binds insulin. Because of these simi-
larities, investigational experiments have also been conducted on 
insulin antibody complexes to see if more information can be ob-
tained as to the nature of the insulin protein complexes. A brief 
review of antibody structure is th(~refore useful in order to aid 
in understanding the nature of these types of insulin complexes. 
Antibody Structure 
~~~--·- --~~~~ 
Antibodies of the gamma G class have a molecular vrnight of 
about 150,000 and when their rate of sedimentation is measured, 
under the force produced by hibh-speed centrifucation, they are 
found to have a sedimentatio~ coefficient of about 7 Svedberg units. 
When treated in strong urea solutions with agents such as mercapto-
ethanol, which reduce disulfide bonds, they regularly fall apart 
into small components. These co~ponents consist of two groups of 
polypeptide chains ·which differ in size. The smaller is 
termed the light (L) and the larger the heavy (H) polypeptide 
chain. The molecular wei3ht of light chains from rabbit gamma 
globulin is about 25,000, ~hile that of the heavy chain is 50,000. 
Figure III shows how these chains are attached in an intact r.iole-
cule. It will be seen that each L chain is attached at the car-
boxy terninus by one disulfide bond to a heavy chain and that 
two heavy chains are also linked together by disulfide bonds. 
Before the chain structure of immuno;lobulin G (IcG) was 
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known, it had already been discovered that the enzymes papain and 
pepsin, which hydrolyze peptide bonds specific for each enzyme, 
could split IgG antibodies into large fragments which retain many 
of the biological properties. Figure III shows where the site of 
cleavage occurs. Papain splits the molecule into three pieces, 
two of which, termed Fab fragments, are identical and consist of 
the L chain, linked to the ar:1ino terminus of the heavy chain by 
a single disulfide bond. The third fragment, termed Fe , consists 
of the carboxyl portions of the heavy chain joined together by 
one or two disulfide bonds. The Fab fragments carry one of the 
two antigen binding sites of the original molecule. Since Fab 
fragments are un:L valent they can~1ot agglutinate particles nm: 
form a lattice structure with antigens or lead to specific preci-
pitations. Disruption of the disulfide bond separates the light 
chain from the N terminal-end of the heavy chain, termed the Fd 
fragment. 
The Fe fragment has no antibody activity but contains part 
of the heavy chain which determines various other biological pro-
peties. 
Pepsin treatment yields an F(ab•) 2 fragment. The site at 
which pepsin cleaves the heavy chain is on the side of the disul-
fide bonds opposite from the site of action of papain. Therefore 
the t7w light chains and the Fd fragments of the heavy chains 
remain linked by disulfide bonds into a sin;le molecule which 
carries both antibody cornbinin~ sites. Thus it is bivalent, and 
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apart from being s:r.aller, combines with antigen in much the same 
way as the original molecules would. 
An ti bod;r: Bindin,;1 Sites 
The available data suggest that the antibody combining site 
is composed of certain hypervariable regions within variable sec-
tions of both polypeptide chains (25). The size of the active 
site has been estimated by measuring the affinity of a specific 
antibody for a series of homologous ligands of different sizes. 
In one study, antibodies to dextran were employed. Glucose oligo-
saccharides of increasing size were then tested for their capacity 
to inhibit the specific anticen-antibody reaction. Maximum inhi-
bition was found with six residues but 90.% of the activ-il:y could 
be inhibited by a tetraner (25). It was also found, by reacting 
antibodies Yli th che1:1icals which modify certain amino acids, that 
the a.nine acid most frequently i:~plicated by such experiments is 
arginine. It is estimated that of approximately 650 a'Tiino acid 
rGsidues of a light heavy chain pair, between 15 and 150 are in-
volved in the antibody combinin~ site. 
The combination between antigen and antibody is reversible 
and does not involve stable chemical bonds, although formation of 
some reversible hydrogen bonds does occur. It is thought that the 
three dime:1sional arrangement of amino acids at the combining site 
presents a surface pattern co~plimontary to the haptcn or to the 
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~· 1 d ~ . t th t• par icu ar e erminan group o~ e an igen. Figures IV and V 
show how this might occur. The forces binding the two together are 
mainly due to the presence of oppositely charged groups in close 
contact, ionic bindine; and partly van der \'laal's forces which act 
between molecules independently of their charge and whose strength 
falls off very sharply with the distance between them. The strength, 
therefore, depends to a large extent on the preciseness of fit 
and the nearness to which the co:.1ponents can approach one another. 
The forces are usually maximal at physiological p~I and ionic 
strength, and at pH values between 3 and 4 or above 10.5 they are 
often so weak that antigen antibody complexes dissociate. 
..... 
0 
IA 
Figure IV 
Figures IV and V are diagra~s to illustrate the shape of tho 
combinins site of a molecule of antibody ac_ainst the hapten group 
and the shape of ha pt en 6roup itself, of,a related 
is known to cross-roact strongly, and of another hapten ~hich cross-
reacts \'e:·y .,,"" "'1,.] v ( :,1rO'"" - •• _c;;..!i... -v • ,;.,' ... .:.l Pauling L. ( 1948) }~ncl ca vour 7, 43.) 
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ILLUSTRATION SHOWING HOW A~TIBODY BINDING MIGHT CCCUR 
Hapten 
2 Related Strong Reacting Hapten 
3 Weakly Reacting Hapten 
Figure V 
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CHAPTER V 
MATERIALS AND METHODS 
-
Materials 
1. Solvents 
Heavy water, warranted to contain a minimum of 99.75% n2o 
- Isotopes Inc. Westwood, New Jersey 
2. Oral Hypoglycemic Agents and Investigative Materials 
Chlorpropamide 
- Pfizer Inc. Brooklyn, New York 
Lot # 07332-17000 
Phenf ormin 
- USV Pharmaceutical Corp~ Yonkers, New York 
Lot # CUrI-A-148 
Acetohexamide 
- Eli Lilly Co. Indianapolis, Indiana 
Lot # 48E72 
SodiQ~ Tolbuta~ide 
- Upjohn Co. Kala'Tlazoo, Michigan 
Lot # gp9G4G9 
d-Biotin 
- Sigma Chemical Co. St. Louis, Missotiri 
Lot # 31c-2300 
Heparin 
- Nutritional Biochemicals Corp. Cleveland, Ohio 
3. Immunological .Materials 
Anti Insulin Ser~~ 
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- Wellcome Research Lab. Beckenham, Kent, England 
Lot # K4273 
Insulin Binding Reagent 
- Wellcome Research Lab. Beckenham, Kent, England 
Lot# K1918 
Human Insulin Standard 
- Wellcome Research Lab. Beckenhari, Kent, England 
Lot # K3139 
4. Buffer Solutions 
Buffer A - 40mM phosphate buffer, pH 7.4, for dilution of antisera 
and iodinated insulin. 
7.0 gms sodium phosphate monobasic-monohydrate 
0.25 gms domiphen bromide (Mann Laboratories, No. 6405) 
1.0 gm polyvinylpyrrolidinone (Matheson Coleman and Bell 
Norwood, Ohio) 
Sodium Hydroxide, 2N, to pH 7.4 
Distilled, de-ionized water to 1 liter pH readjusted to 7.4 
Stored at 4°c 
Buffer B - Buffer for dilution of standard insulin and plas~a 
samples. 
9.0 gms sodium chloride 
Buffer A, to 1 liter 
Stored at 4°c 
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Buffer .£ - Washing buffer for washing antibody precipitates. 
39 gms polyvinylpyrrolidinone (Matheson Coleman and Bell, 
Norv.rood, Ohio) 
Buffer A, to 1 liter 
Stored at 4°c 
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Methods 
1. Extraction of Serum Fraction with "Bound Insulin" Activity 
Method of Antoniades (1) 
A 100 x 2.5 cm column r:as packed with Dowex Analytical Grade 
resin, AG50-x8, (Bio-Rad Laboratories, lot #5369). The resin was 
first equilibrated with 0.15 ll NaCl for three hours before being 
packed in a glass colu:r.m to a final wet volume of 175 ml. After 
packing, two liters of O.l5N - Na2HP04 were passed through the col-
unm, making the final pH 6.6. A 100 to 300 ml sample of pooled 
human serum was passed through the colur:m at a rate of 8 ml/minute. 
After passage of the scrun, the column was v:ashed with two resin 
volumes of 0.15 IT NaCl, followed by elution of the "bound" insulin 
fraction vii th one resin volume of o. 1 N NH4 OH. The pH of the eluate 
was monitored with a Radioaeter pH meter, and kept at 7.0 ;;: 0.5 
with 2N H2so1+. After elution of the "bound" insulin fraction, 
the eluate rras lyophilized o.r1d stored as the dry powder at -1 o0c. 
2. Modified Isolation of the ig vivo Insulin Protein Complex 
Because of the fact that the :previous :procedure caused 
problems of reproducibility in isolating an ascayable 11 bo:.ind11 
insulin fraction, and the fact that it required a hic.;h pH of 
approximately 10, which might cause some denaturation of the 
protein, a nodified procedure, reported by Guenther and McDonald, 
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was employed for the isolation of the "bound" insulin (41). 
A volume of 500-1000 ml of pooJed human serum was stirred 
for 45 minutes at 4°c with approximately 10 gms of Sephadex C-50 
resin, which had been allovred to hydrate overnight prior to use. 
The mixture was then filtered on a Buchner funnel. The recovered 
resin was subjected to repeated washings, using 2-3 liters of 
0 
cold (4 C, approx.) de-ionized water. A pre-cooled, jacketed 
column, measuring 100 x 2.5 cm, was packed with the pre-washed 
resin. To remove further anionic and neutral proteins·, a 0.005 
N aqueous solution of (rm4 )2co..,., pH 7.8, was run through the - I ~ 
column. Once a steady base lLrn vms reached on a UV monitor (LKB) 
a gradient of a2lll:10'.1iu:n carbonate> fro~n OQ005 N to 1.0 ?I, at a pII 
Of 7. P, at 25°c, 1. d o was app ie • The flow rate was adjusted to 0.5 
ml per minute. 
The different elution peal:s were pooled and the pH was adjus-
ted to 7.3 .:!: 0.1, at 25°c, using acetic acid. Following pH ad-
justment, the pooled solutions were de-salted and concentrated 
vd.th an Ar;;icon Ultrafiltration apparatus, using a UM 10 mei:1brane 
which permits passage of substances below a MW of 10,000. C' • ,.)lD.C8 
"bound" insulin has a H'.'i much er eater than 10, 000, it would be 
retained. This filtration procedure also served to remove the 
last traces of free insulin i'!h:lch might have been trapped by the 
Sephadex rosin. The concentrated eluates were freeze-dried. 
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3 Optical Rotation Studies • 
When investigating a molecule by optical rotation studies, 
one can use plane polarized light. Plane polarized light nay be 
described as the vector cun of t~o circularly polarized rays, one 
moving clockwise ("right-handed") or counterclockwise ("left-
handed") traveling in phase. Alternately, the circularly polarized 
beams may be used directly in a difference absorbance measurement. 
The measurement of the angle of rotation of plane polarized light 
when it is plotted as a function of wavelenc;th results in an op-
tical rotatory dispersion curve (ORD) while the plot of the dif-
ference absorbance of circularly polarized beans results in a 
circular dichroism curve (CD). 
Light being electro-;:iagnetic in origin interacts with a 
molecule by causing a r:iomentary change in the relative spacial 
positions of positive nuclei and negative electrons. A molecule 
containing a plane or center of synmetry will interact equally 
with left and right circularly polarized beams. However, a di-
syDr1etric molecule vdll cause a pre fcrential interaction with one 
of the circulo.rly polarized bea;;:s. In an absor]_:ltion region this 
interaction will be seen as a differential absorption (a dichroism) • 
. , 
Circular dichroism bands are closely related to absorption bands 
and oft on tbe circular dichroisn r:Jaximum coincides with an absorp-
tion maximum. Tho absorbance diffe~ence botween the left and 
right co::1ponent::, L.A ecnw.l.::; 6 A is dependent on concentra-
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tion and optical path length and leads to the term "molar circular 
dichroism, 11 6:S, which is equal to 6A/cd, when: 
c = concentration in ~oles per liter 
d = optical path length in centimeters -
For use in protein solution, the molar circular dichroism 
term can be reduced to a concentration of 1g/100ml and an optical 
path of 1 cm. 
symbol 6~ 11 % cm 
This reduced circular dichroism is given by the 
ic1.: 
or 6D ' 0 lcm• 
---
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A. Circular Dichroism Measurements 
Circular dichroism spectra were run on a Jasco Model ORD/ 
UV-5.recording spectropolarimeter. Sa~ples were run in 10 mm or 
l mm cells especially designed and checked for optical rotation 
studies. The instrument was calibrated before each set of exper-
iments using camphor sulfonic acid. A sensitivity setting of 0.02 
was used, at a gain setting of 7, and a chart speed of 4 mu/cm. 
All samples were run in phosphate buffer, at pH 7 .4, at a room tem-
perature approximating 27°c. 
4. Radioimmunoassay of Insulin 
The radioimmunoassay carried out was a form of the procedure 
of Hales and Randle (43). The method uses iodine-125 antisera 
prepared to crystalline pig insulin, in guinea pigs and anti 
guinea pig serum prepared in rabbits. The insulin in the test 
sample competes with added raiioactive insulin for binding sites 
on the antibody (See "'. L'lGUre II ) • The insoluble insulin-antibody-
antibody complex is filtered out and measured for radioactivity. 
The level of activity is related in an inverse manner to the 
amount of insulin present in the test sample. 
A. Reagents 
Insulin binding reagent - Wellcorne Brand # MR48, obtained 
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from Wellcome Research Laboratories, Beckenham, Kent England. 
The commercial preparation is prepared as stated previously by 
forming antisera to crystalline pig insulin in guinea pigs. After 
adjusting the titre of the anti-insulin serum, it is diluted in 
buffer containing ethylenedia~ine tetraacetic_acid and mixed with 
a predetermined a~ount of the anti guinea pig precipitating serum 
prepared in rabbits. The mixture is allowed to react at 4°c for 
18 hours and is then freeze dried. When reconstituted to a volume 
of 8 ml, each vial contains guinea pig serum precipitate diluted 
to in 16,000 and 0.03 M EDTA in buffer A. This reagent binds 
approximately 40% of the standard dose of 250 picograms iodinated 
insulin (6uU). 
B. Working Solution of Iodinated Insulin 
Iodinated insulin 125, #IN 38, was obtained from Amersham/ 
Searle Corporation, Des Plaines, Illinois. The material used 
was supplied in 0.1 ug quantities and solubilized in phosphate 
buffer, 40 mH, pH 7.4 containing bovine plasma albumin 0.5%. 
The minimum specific activity was 50 uci/ug. The commercial 
material is prepared from specially purified crystalline ox insulin 
by iodination with iodine monochloride. Unbound iodine is removed 
by gel filtration. 
c. Buffer Solutions 
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Buffer solutions A, B, and C were used as listed on pages 
30 and 31. 
D. Assay Procedure 
Insulin binding reagent was reconstituted with 8 ml of 
distilled water and 0.1 ml aliquots were dispensed into culture 
tubes. A volume of 0.1 ml of the unlabeled insulin solution, 
either sample or standards, was added to the culture tube con-
taining the binding reagent. Along with each series of experiments, 
blanks consisting of buffer B, were also sot up. All tubes were 
mixed with a Vortex mixer and then placed in a refrigerator for 
. , at 40r". six nours v All of the above procedures were carried out 
· l' t 4°c. in a co a room a 
After six hours the tubes were removed from the refrigerator 
and returned to the cold room. One-tenth ml aliquots of insulin 
125 working solution were added to the tubese The tubes were 
again mixed and returned to the refrigerator for eighteen hours. 
At the end of eic;hteen hours, the tubes were again placed in 
the cold room. A ;,Ullipore fil tra ti on apparatus was prepared by 
first placing the filters onto the 18 wells of the apparatus and 
applyinc vacuum. The meBbrane filters were presonked overnight in 
Buffer C and applied to the filter holders by means of a pair of 
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forceps. The contents of each tube was carefully applied to the 
filter and the tube washed twice with approximately 1 ml of cold 
Buffer C, the washing buffer solution being drawn up into the same 
pipette and applied to the filter. After samples were applied to 
the filter, the apparatus v:as disassembled and each filter was im-
mediately inserted into a counting vial using a pair of forceps. 
The filters, now contained in the counting vials, were dried for 
a period of 10 minutes at 110°c. When the vials had cooled to 
room temperature after the drying stage, 10 ml of scintillation 
fluor was added to each vial. The vials were then placed in a 
Beckman LS-250 Scintillation Counter, allowed to dark adapt for 
two hours and then counted. The samples were allowed to count 
to a 3% error. The gain control was set at 280, optimu::i'.1 operating 
efficiency for the instrument at this point in time. A full 
window isoset was employed in the counting. The external standard 
ratio system of the instru~ent was used to monitor the relative 
quenching of the samples and to determine whether or not correc-
tions for quenching would have to be applied to the results. 
The external standard ratio reading reflects the efficiency of the 
count for each individual sample. If there is a considerable 
variation in the e.zternal standard ratios of, the individual samples, 
a correction factor must be applied to the results of tho count 
to compensate for a varying efficiency in the counting of differ-
ent samples. 
If the external ata:1dard ratio readings are unifo:r·m, hO\'l-
jiP 
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ever, this reflects the fact that the efficiency of the counts 
is uniform enough to make any correction factor unnecessary. It 
was found that the sa'11ples were very uniform with respect to· the 
external standard, which meant that no quench correction was ne-
cessary. 
5. Deuterium Exchange 
The technique of deuterium exchange represents a generalized 
method for the determination of active hydrogen. Che~ically reac-
tive hydrogen atoms such as those bonded to oxygen and nitrogen 
equilibrate rapidly with the deuterium of D20 to establish a sta-
tistical distribution of active hydrogen and deuteriu~ between the 
exchange compound and n2o. Hydrogen bonded to carbon will exchange 
with deutori u:n but this ex chance is extremely slow, boing of the 
order of days and months. Under such conditions, it is impossible 
to define una'11biguously exactly what is meant by active hydrogen, 
but in this discussion it will be understood to be that hydrogen, 
which exchanges rapidly (in the order of minutes and seconds) with 
deuterium. 
Rapid hydrogen-deuterium exchange can be explained simply, 
by a hydrogen-bonding ~echanism (4lt). An alcohol and n2o may 
become associated, using the example of Harp (44), in a randomly 
constructed polymer of the form shown below. 
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-[ H-r-~g--H-~-- ] -n 
The hydrogen and deuterium rapidly lose their identity with 
respect to a specific oxygen atom because of a shifting and re-
establish.r:ient of bonds in the following manner. 
( -H---0-D---~H 
~ D 
Thus, at equili~riur.i, one finds a statistical distribution of 
active hydrogen and deuterium between the exchanging compound and 
n2o. The equilibrium mixture is composed of ROI-I, ROD, D2o, HOD 
and n2o. If a sa..'1lple D2 0 mixture contains 3 atoms of active hydro-
gen to 97 ato;;rn of deuter.ii u::n, then at equilibrium the ratio of ROii 
to ROD will be 3 to 97. 
The same sort of argu:::ient applies to a peptide or a protein 
will.ch is dissolved in D2o. A rando:n distrj_bution of active hydro-
gen and deuterium exists between the exchanging compound and D2o. 
However, because of the tertiary properties of protein, the ex-
change of side chain and peptide hydrogen in the interior of the 
molecule becomes blocked or extremely slowed down to the order of 
days. It seems evident, therefore, that by altering the confer-
mation of the molecule, a particular group may become exposed and 
an increase in the number of active hydrogens would be expected. 
To measure the number of active hydrogens, the sample is 
dissolved in n2o and the mixture is stirred for a half hour. All 
of the exchanged hydrogens, regardless of their origin in the equi-
librium mixture, beco:ne bonded to ox:lgen atoms and the OH bonds 
formed sho\'1 the typical hydrogen-bonded OH stretching which results 
in an absorption band ~t 2.97 microns: ·Thus, after suitable 
calibration, the active hydrogen content of the unknown can be 
determined from the OH absorption of the D20 phase. All samples 
were run in a O. 025 r.:un CaF2 cell at the slov1 scan speed on a 
Perkin Elmer Model 337 Grating Infrared Spectrophotometer. The 
range from 2.5 to 3o3 microns ~as scanned. A calibration curve, 
using H2o as the standard, was prepared. The number of moles of 
active hydrogen were calculated from the following formula of 
Harp (L~4) 
Moles of active hydrogen/gram of sample -· 
Moles of ffiI/ liter of solution 
grams of sample/ liter of solution 
where moles of OH/ liter of solution is a corrected term, obtained 
from the calibration curve representing corrected absorbance vs. 
concentration. 11 corr0cted o.bsor:jance11 is absorbance corrected for 
cell blank and residual D2o background. 
The calibration curve is prepared by using water (H20) in 
a concentration range of 0 to 6 moles of active hydrogen per 
liter. Absorbances equal to log To/T are determined for the 
calibration solutions where To equals the transmittance at 2.50 
microns and T equals the transmittance at 2.97 microns, both 
transmittances being measured relative to air. The transmittance 
at 2.5 microns is used as a base line reference point since n2o 
and the sa~ples analyzod have a maximum transmittance at this 
wavelength in the range scanned. From these determinants a cali-
bration curve is constructed for use in the analysis of unknown 
samples. 
CHAPTER VI 
RESULTS AND DISCUSSION 
------
The first area of research to be discussed will be that of 
the radioimmunoassay. An ILA extract, isolated according to the 
procedure published by Antoniades and co-workers was used in the 
beginning phases of experimentation (1). This extract was added 
to obtain a concentration of 6 mg/cc to a 0.037 M solution of 
each of the folloqing substances: three hypoglycemic sulfonylure-
as, tolbutamide, chlorpropamide, and acetohexamide (See Figure 
VI ) and with one biguanide, phenformin (See Figure VII ). The 
results of this assay are shown in FigureVIII. The ILA extract 
showed an activity of only 0.7 uU/mg of resin eluate. Chlorpro-
pamide and phenformin were essentially inert in causing a release 
of free insulin; acetohexa;nide, however, and tolbutamide caused a 
24.0 and a 43.0 uU/mg of resin eluate release, respectively. These 
latter two compounds, although minimally, are somewhat effective 
in that they release trace quantities of free insulin-like mater-
ial. However, the concentration of the various oral hypoglycemic 
compounds used was .037 Molar, a concentratipn which is quite high 
when compared to the normal physiological usage concentration of 
1.4 m:1. The question of whether these drugs may have some effect 
on the assay itself, that is, the binding equilibrium of the radio-
immunoassay, cannot be ignored, especially when one considers the 
CH __ff"\.__so -NH-CO-NH-C H 3~ 2 4 9 
Tolbutamide 
Cl -0-so2NH-CO-NH-C3H7. 
Chlorpropamide 
CH3-C ~ 502-NH-CO-NH-@ . II~ 
0 Acetohexamide 
STRUCTURE OF SULFONYLUREAS 
Figure VI 
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~CH -CH -NH-C-NH-C-NH  2 2 II II 2 
NH NH 
phsnethylbiguanide 
STRUCTUI:li: OP PHEHETHYLBIGUANID:S 
(also referred to as Phenfor~in and DBI) 
E'ie;ure VII 
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fact that tolbutamide will cause physiological reactivity of anti-
body bound insulin in the rat diaphragm assay (46). To help an-
swer this question, further radioimmunoassays were carried out. 
Radio~mmunoassaz of ILA "Sxtract and Antibody Bound Insulin Complexes 
The radioimmunoassay procedure discussed was carried out 
using ILA extracts which were obtained using the procedure des-
cribed by Guenther and McDonald, (41) and also antibody bound in-
sulin complexes obtained by combinine antibody vd. th a quantity of 
insulin slightly in excess of the binding capacity of the antibody. 
The aJitibody-i:nsulin co;;iplex, being solublo, could be assayed with 
the radioimmunoassay since it would not be retained on the filter. 
As stated in the introduction, it is hoped that this insulin com-
plex will serve as a model system for the j_n vivo bound-insulin 
complex. 
The new ILA extract was utilized in this set .of radioimmuno-
assays at a concentration of 20 mg/cc and the antibody bound insu-
lin complex was used at a concentration of 3.46 ug/cc. The fol-
lowing compounds were assayed ~ith each compJ.ex, at a concentra-
tion of 0.1+ mg/cc, whic!i is approximately their physiological 
concentrations (at 1.4 mM/l); tolbutamide, acetohexamide, phen-
ethylbiguanide and chlorpropamide. Also heparin and biotin were 
assayed at a concentration of 50 ug/cc, (0.2 rn>I/l). To help 
eliminate the possibility of any interference from these agents 
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with the assay procedure itself, standard curves were prepared 
in the presence of each of the individual compounds. Figures IX 
to XV show these curves plotted according to the method of Hales 
and Randle, using c0 /ci versus concentration, to obtain a linear 
plot (43). The theoretical background for this procedure is des-
cribed by Hales and Randle as follows: 
Suppose: 
Then: 
Then: 
i 
--
the concentration of unlabeled insulin 
co = the radioactivity (cpm) of the insulin-antibody 
complex when i is zero 
-
Ci -· the re.dioac ti vj_ty (cpm) of the insulin-antihody 
complex when the concentration of unlabeled is i. 
I and I ~ the amount of 1251 - labeled insulin bound bv 
-0 ,; 
antibody under these conditions. 
x - specific activity of the labeled insulin 
~ - concentration of 125I - labeled insulin 
.... o 
co = x • Io 
c. 
J_ = 
x • I 
co/ci = I 0/I 
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which is in the form of y = mx + b. There fore c I c. · viill be 
0 l. 
linearly related to i and c /c. will be unity when i = zero. 0 l. 
This theoretical relationship will only hold in practice 
if the affinity of antibody for 125r-labeled insulin and unlabeled 
insulin is the sane and if the a':l.ount of insulin bound oy antibody 
is indopendent of the concentration of the insulin. Departure 
from this theoretical relationship, in practice, will not inter-
fere with the practical assay of insulin as long as the latter is 
made to refer to a standard solution of the hormone. 
The curves in Figures IX to XV demonstrate that the various 
chemical agents used affect the assay procedures by changing the 
slope of the stand2rd c~rvsa indicating that the bindin~ of anti-
body to insulin is altered. It appsars from these curves that 
tolb:1t,:::L1ide and hepc'.]'.'in ei1~:a~1ce the binding capac~ ty o:f the anti-
body system Tihile DBI and c~lorprop~nide inhibit it. On the other 
hand acetohexrujide and biotin have little effect on tho binding 
capacity causing possibly only a slight decrease. If we let the 
saline curve repr·esent e, factor of ui1i t;)' for binding capacity, 
Table I t~en sho~s how uuch the binding capacity of the system 
is altered relative to the saline standard curve. 
By computinc the equation for the standard curve the a~ounts 
of i~nunolosically active compounds were calculated. Table II 
shows t!::ese results for 11 bonnc. 11 insulin a::i.d the insulin anti body 
complexes. In the 11 bound 11 insulin co;aple::cs, it is evident tlmt 
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TABLE I 
BINDING CAPACITY CHA~W~ RELATIVE TO THE 
SALINE STA2mARD IHl·IUHOASSAY CURVE 
Saline 1.0 
Tolbutarnide 2.5 
Heparin 2.9 
Acetohexamide 0.9 
Biotin o.8 
Chlorpropo::11ide O.L~ 
DBI 0.3 
(Numbers over 1 ::: increase in binding capacity, 
Numbers u~der 1 = decrease in bindin~ capacity) 
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TABLE II 
IMMUNOASSAYABLE INSULIN ACTIVITY IN THE 
PRESEI'ICE OF CHZMICAL AGENTS 
Sample Insulin Activity 
Blank-bound insulin (BI) 1. 1 uU/mg extract 
Tolbutamide-BI 2.2 II 
Biotin-BI 1 .o II 
Heparin-BI 0.53 II 
Acetohexamide-BI 0.03 II 
DBI-BI 2.9 II 
Blank-antibody (AB) 26 mU/mg antibody 
Tolbutamide-AB 17 II 
Biotin-AB 47 fl 
Heparin-AB 11 II 
Acetohexamide-AB 25 II 
Chlorpropamide-AB 75 II 
DBI-AB 135 II 
' 
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DBI shows the greatest activity, with tolbutamide also showing 
activity. On the other hand biotin appears to have little effect 
while heparin and acetohexamide appear to inhibit activity. 
In the experiments conducted on the insulin antibody com-
plexes, DBI again shows the greatest activity, with chlorpropamide, 
too, showing high activity. Tolbutamide and heparin appear to 
inhibit activity while acetohexamide and biotin show essentially 
no change or only a moderate increase, respectively. Also illus-
trated by the data from the insulin antibody complexes is what was 
predicted by the standard curves and explained previously, that is, 
the alteration in binding capacity of the insulin antibody system, 
by the chemical ac;ents studied. As predicted, tolbuta:-1ide and he-
parin increase binding capacity, thereby inhibiting releaso and 
this is what has occured. Also, binding capacity was predicted to 
decrease with DBI and chlorpropamide and remain unchanged or in-
crease slightly with acetohexamide and biotin,respectively. This, 
again,is what has occurred. 
ImmunolRical Insulin 
In both types of complexe~ the increase in activity caused 
by sor:ie of the agents appears to be a significant quantity. 
However, it is not really so if comparison is made to physiologi-
cal activity. Experiments conducted in the laboratory by co-
workers indicate about a ten-fold greater physiological activity 
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with some of the agents. 
A logical interpretation of these experimental results 
would be that, in addition to the effect which some of the hypo-
glycemic compounds used might have in causing an actual release 
of insulin from its bound form, they may act in another complete-
ly different ~anner. This latter effect may possibly he due to 
an ability of the compounds to change the confor~ation of the in-
sulin protein co:nplex, thereby rendering it physiologically active 
without involving an actual release of the insulin from the insu-
lin-protein co:-nplex. This concept is credible because of the fact 
that it has been shown that insulin can cause its physiological 
effects by disulfide binding to a receptor site on the cell mem-
brane (63). Further discussion of this phenoue~a will be taken 
up later. This concept would, then indicate that insulin does not 
have to pass through the cell ~embrane to cause its effect but would 
only have to be available to bind to the cell membrane. 
Circular Dichrois~: Evidence for Conforaational Chan~e 
Circular dichroiGD spectra ~ere run o~ the same antibody 
insulin complex and usin~ the sa~e hypo;lycemic compounds which 
were enployed in the ~Jrovious :--aclioi:n~ri1.moassay studies. r.I1he con-
centrations of all rea;ents were ~aintained at the sa~e level as 
in the previous studies. Figures XVI to XXI sho~ these curves, 
Ficure XXI beins a composite of all curves. The curves Rre plotted 
~ 
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using reduced circular dichrois~s versus wavelength, the former 
being A1 - AR expressed at 
meter. 
r % and at a pathlength of 1 centi-
o 
The compounds investi;ated, as shmm by these curves, pro-
duced changes in the confor8ation of the antibody-insulin complex. 
The region studied, 320 to 21+0 nr.1, is indicative of disulfide bond 
and aro~atic group interactions. The circular dichroism effects 
of the antibody-insulin co;;iplex, in the region studied, are weak. 
and complex, however, ther·e is no reliable alternative methods 
with which to check dynamic conformation j_n solution. Tho con-
clusions which were reached, based on this data, must therefore 
be considered to be somewha.t speculative in nature. A few remarks, 
however, may be pertinent. 
The complex seems to show a blue shift (a shift in the 
spectra to shorter wavelength) over that of the single conponents 
as shown in the spectra of other investigators ( 62 and 68) o 
The addition of heparin causes even more of a shift. This change 
in spectra may be indicative of tyrosine and phenylaline transitions 
of insulin possibly with a contribution fro~ disulfide interactions. 
The remaininc; coDpounds investicated caused a decrease in the 
circular dichroism of th2 co::1plex at 265 nm (;lnd 250 nm, indicative 
of a chanGe in conformation due agai~ possibl~to phenylalanine 
and tyrosine transitions. This is based on the investigations 
of Ettinger that have sh01.m phenylalanine, tyrosine, a.nd their 
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derivatives to show circular dichroism transitions between 250 
and 274 nm (32). 
Deuterium exchange experi~ents were conducted on antibody-
insulin complexes and on bound insulin complexes, using heparin 
and tolbutar:iide. Th .. i.s data is shown in Table III. In every case, 
the addition of one of these cor,rponnds caused a change in the 
number of active hydrogens present in the complex. However, 
all of the changes represented a reduction in the number of ac-
tive hydrogens which is indicative of a conformational change in 
these conplexes due either to the foroation of bound water which 
would thereby reduce the a::.1ount of OH stretch measured, or b;y a 
dilution effect of the D~O causod by the release of bound water 
L 
trapped in the insulin protein cor:1plex. This latter effect may be 
more likely what has occured in light of thG interpretation of 
the circular dichrois~ studies. 
Samples 
Insulin - Blank 
Antibody - Blank 
Antibody + Insulin 
BI - Blank 
Tolbutamide - Blank 
Tolbutamide + BI 
BI - Blank 
Heparin - Blank 
Heparin + BI 
BI = "Bound Insulin" 
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TABLE III 
DEUTERIUM EXCHAl1JGE DATA 
Moles of Hydrogen Released per 
gra::1 of exchanging Compound 
1.37 x 10-2 
3.69 x 10-2 
1. 65 x 10-2 
4.05 x 10-2 
6.4 x 10-3 
1. 13 x 10-2 
2.5 x 10-2 
9.0 x io-2 
3.2 x 10-2 
BI used vii th tolbutar.iide v:as isolated according to the procedure 
of Antoniades.(1) 
BI used with heparin was isolated according to the procedure of 
Guenther. (41 ) 
CHAPT:sR VII 
FURTHER DISCUSSIO:r Alm CONCLUSIONS 
The previous exporimenta.l material has shown that two 
effects on insulin-protein complexes occur in the presence of 
oral hypoglycemic agents. These effects involve the liberation 
of free insulin and a conformational change. 
The fact that physiological insu]j_ n activity, as repcrted 
by Guenther and McDonald, (41) is greater than accounted for by 
free insulin release would indicate that the conformational modi-
fication is the more important effect in eliciting insulin-like 
activity. The follO\'ling question can then be raised: How can 
insulin remain bound as an integral part of an insulin protein 
co~plex and still exhibit physiological activity? This seeming 
contradiction may be resolved by considering the fact that insulin 
does not need to penetrate the cell in order to cause its effect 
but only needs to bind to the cell me~brane. The studies of 
Wohltman and Nara.hara have shown that insulin which is bound to 
cell membranes exerts a physiological effect on these tissues 
even after prolonged washing in insulin fre~ solution (83). 
Ultrastructural studies of Barrett and Ball also suggest that the 
first event of insulj.n action must be its adsorption to the cell, 
specifically, to the cell membrane (17). Their studies, using 
electron uicroscop~, de~onstrated the induction of an inva~ination 
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in the mewbrane of the epididy::-nal adipose tissue cell. The ques-
tion remains, then, hovr does t:he combination of insulin vri th a 
specific receptor at the cell surface actually occur? 
Schwartz proposed that a sulfhydryl-disulfide (SH-SS) inter-
change reaction might be the basis for the initial reaction (69). 
Noting that the disulfide ring in oxytocin is of approximately 
the same size as the intrachain disulfide loop of the A chain of 
insulin which is known to be essential for activity, it was dis-
covered by Mirsky that syntbotic oxytocin exerted an insulin like 
action on the utilization of glucose by rat epididymal adipose 
tissue and reduced the free fatty acid concentration in the plas~a 
of normal and alloxan-diabotic dogs (60). Further investigations 
on the question of insulin attac1'~'1lent by Cadenas, showed in per-
fused rat heart that brief exposure to the sulfhydryl blodker, 
N-ethylme.leh1ide (lJEM), abolishes subsequent stimulation of glu-
cose transport by insulin(23). However, such inhibition by N~I does 
not occur if the hearts are first treated with insulin. Edelr.1an 
and Schwartz have shown, by further investigation using Nli2-1 and 
labeled insulin, that this disulfide interaction is not interchain 
but rather intracbain involvement \'lith the cell receptor (27). 
Figure XXII shows the proposed binding ;n8chanisr.:i. 
This pr-oposed bindinc; n18chanir::;m of insulin to the cell re-
ceptor could be the answer to the question of how protein bound 
insulin is still able to exert its phys::i.oJogical effect, that 
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is, by combining with the cell r.iembrane through sulfhydryl-disulfide 
reactions instead of actually penetrating the cell membrane. In 
the proposed r:iechanisms shown in Figure XXII, part A shows how, as 
Rieser (63) explains, hormone receptor disulfide sulfhydryl reactions 
could occur with a subsequent change in the tertiary structure of 
the membrane proteins thereby altering the membrane barriers that 
limit diffusion of water and specific solutions. In part B is 
shown how disulfide-linked membrane fibrils could be separc;ted 
by disulfide interchange thereby causing pores in the membrane 
to open up for the passage of solution. 
Although a mechanism for physiological action of insulin 
has been proposed, the question of hov1 the "bound" insulin mole-
cule becomes activat0d still remains. To help answer this question> 
it is necessary to turn to the tertiary structure of insulin as 
elucidated by Blundell from x-ray crystalographic studies (20). 
Figure XXIII shovs the structure proposed by Blundell. The most 
obvious stabilizing forces result from the disulfide bonds. 
B? - A? is on the outside of the molecule while B19 - A20 is 
slightly nore concealed but still accessible to solvent. The 
A6 - All intrachain disulfide bond is completely buried and forms 
part of the non-polar core of the insulin molecule. As Blundell 
has shown, the general dis~osition of these groups is consistent with 
the ease with v/hich the interchain bridges are reduced while the 
intrachain disulfide is highly unreactive to chemical agents. 
830 
PROPOSED TSRTIARY ST~UCTURE OF INSULIN 
Figure XXIII 
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Another iDportant feature of this structure is the existence of a 
completely non-polar core, as Blundell states, "The regions of 
non-polar incrachain contacts are brought together in the coDplete 
molecule and define a hydrophobic center comprising the residues: 
B6, B11, B15, and A16 leucines; B18 valine; B24 phenylalanine and 
the phenyl ring of B26 tyrosj_ne; the A6 - A 11 and part of the A20 -
B19 cystines. 11 (20) Figure XX!V shows the schematic representation 
of Edmundson and Schiffer for the non-polar core (28). This 
non-polar core may be the reason for the change observ·ed in the 
deuterim:i exchange data, namely, a reduction of solvent OH. This 
may be explained by the fact that when insulin is bound as an inte-
gral part of an insulin-protein cor;1plex, as in tho case of insulin 
hexamer formation, solvent is excluded from the exposed non-polar 
face of the nomo~er whereas when a conformational change occurs, 
solvent may be taken up. Blundell states, "Whenever sequence 
variations involving substantial modification of the non-polar 
core or stabilizins residues are made, the insulin is found to 
be inactive... Indeed, it has been emphasized that a.viy change in 
conformation results in a decrease in biological activity of in-
sulin." (20) 
The deutoriu~ exchange data and the ci~cular dichroism 
spectra shorrn in the experimental section indicates a definite 
change in the conforDatio~ of the insulin protein complex in the 
presence of the hypo;lyce:nic co:apou::-:ids investigated. The chance 
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in conformation observed may be a return of the insulin molecule 
to a more rando~ or native form of conformation from that formed 
by the association of insulin with protein. This :nay be explained 
by lookinG at the antibody coDplex of insulin. 
Antibodies against a helical structure tend to stabilize 
or induce the helical tendency of polypeptides (68). This return 
to the native forn, that is, a co~bination with the cell membrane 
through sulfhydryl-disulfide interaction, upon the addition of 
chemical agents, may, then, be what allous the insulin-protein 
complex to exert its physiological action. 
In conclusion, it has been sho~n that the addition of oral 
hypoglyce~ic cc~pcu~ds to insulin co~ple~es causeG e dual effect, 
na;nely that of free insulin release and that of conformatio~1al 
change, the latter appa~ently beinc ~ore significant in relatio~ 
to physiological activity of insulin. Both bound insulin isolated 
from humo.:'1 seruu a21.ci synthetic antibody-insulin complexes appeared 
to be affected similarly. This observation that both cor:i.plexos 
are effecte~ similarly would seem to justify ruling ou~ the pos-
sibility that althouch the isolated bound insulin had so~e conta-
r1inating protein the effect seen in the deuterium exchange studies 
was not attributable to these other proteinci. 
The important role played by a conformational change also 
helps to clear up a controversy that has continued in the liter-
ature for over five years co:1ce:::-ni::-;: the existence of "bound 11 
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insulin. Various investigators have reported that they have been 
able to isolate it while others have been unable to do so. An 
important consideration here is the fact that those investigators 
who have not been able to isolate "bound" insulin have, for the 
most part, used the radioimmunoassay procedure which measures anti-
body-corJbinable insulin onl:'. On the other hand, investi::ators 
who have confirmed the existence of "oound" insulin have used bio-
assay procedures which measure physiologically active insulin. 
The conformational changes induced by the various oral hypo-
glycemic co~pounds also aid in understanding their function, for 
example, phenethylbiguanide is know:.11 to produce a hypoglycemic 
effect in pancreaectomized an.iL1als. It hac been shown previously 
that phenethylbiguanide works on the hcxokinase system (66) but 
now it has also been shown that it can release free insulin from 
its bound for~ and also contribute to a conformational change in 
the protein-insuli::J. complex. 
Of major importance is the demonstration that biotin, a 
vitamin, causes a si11ilar cha:1e:;e in protein-bound insulin and 
at concentration levels which are in the physiological range. 
Thus, this -,.ritamin and the other cm;1pouns which are discussed may 
help the body maintain homeostatis upon glucose load by causing a 
physiological activation of the bound insuli~ complex. Now that 
new mechanisms for the action of the oral hypoglycemic compounds 
have been elucidated, there is no longer any justificatioa for 
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explaining their hypoglycemic action by a single property, for 
example, in the case of tolbuta."llide, the release of insulin from 
the pancreas. 
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APFSNDIX 
A REPRESE:-ITATIVE SA?:JPLE OF DATA DERIVED 
FROM THE RADIOHI:,1UNOASSAY PROCEDURE 
Blanks CPM Corrected s 
Count .Mean -x 
Background Count 393 
Saline Dlank 2054 1661 54 
Bound Insulin 
(BI) Blank 1598 1205 81 
Antibody Insulin 
(AB) Blank 1070 677 69 
Tolbutamide 
Blank. 2907 251 ~· ?i 
Biotin 
Blank 2063 1670 106 
Heparin 
Blank 2693 2300 88 
Acetohexamide 
Blank 1964 1571 87 
DBI Blank 1885 1 Li-92 80 
Chlorprope.i1ide 
2188 Blank 1795 107 
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APP:SNDIX 
COMBINED EXPERHfSNTS 
Samples CPM Corrected s co/ci 
Count Mean -x 
Tolbutamide 
- BI 1307 914 17 2.75 
Biotin 
- BI 1722 1329 25 1.26 
Heparin 
- BI 1915 1522 184 1 • 51 
Acetohexamide 
- BI 1957 1564 38 1 .oo 
DBI - BI 1552 1159 lf0 1.29 
Tolbutamide 
-
AB 1125 732 55 3.43 
Biotin 
-
AB 932 539 24 3. 10 
Heparin 
118? 
-
AB 794 77 2.89 
Acetohexamide 
-
AB 1079 686 38 2.29 
DBI 
-
AB 839 Li-46 50 3.35 
Chlorpro:pamido 
-
AB 1050 657 66 2.732 
83 
APPE?TDIX 
STJUYDARD CURVE DA'l1A 
Samples CPM Corrected s co/ci 
-Count Mean x 
Sali11e 
Standard 1781 1388 71 1 • 196 
2 1866 1473 33 1. 127 
3 1367 974 52 1. 705 
4 1213 820 66 2.025 
Tolbutamide 
Standard 1 2125 1732 98 1.Li-51 
2 1660 i267 46 1 • 9811-
3 1430 1037 84 2.424 
Li- 1139 746 23 3.369 
Biotin 
Standard 1727 1334 104 1. 251 
2 1921 1528 51 1.092 
3 1 GO? 1214 35 1.375 
4 1295 902 83 1 • 851 
Heparin 
82 Stando.rc~ 1987 1594 1 .442 
2 1556 1163 34 1. 977 
3 1220 827 117 2.781 
4 111 6 77.3 45 2.975 
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Acetohexamid.e 
Standard 1 1562 1169 34 1.343 
2 1649 1256 37 1 .250 
3 1348 955 97 1 • 61+5 
Li- 1251 858 87 1. 831 
DBI 
Standard 1882 1489 66 1 .002 
2 1982 1589 34 0.938 
3 1618 1225 103 1.217 
4 1476 1083 35 1.377 
Chlorpro!'o.nide 
o.897 StCJ.ndard 1 239Li- 2001 101 
2 2122 1729 82 1.038 
3 1727 1331+ 44 1 .3Li-5 
4 1117 724 70 2.1+79 
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Standard 
== 
10.4 u~ of insulin per Ell 
Standard 2 == 19. 9 uU of insulin per ml 
Standard 3 == 36 • .5 uU of insulin per ml 
Standard ! 14 :- 62.5 uU of insulin per nl 
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